Litigation Details for Pharmacyclics LLC v. Alvogen Pine Brook LLC (D. Del. 2019)
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Pharmacyclics LLC v. Alvogen Pine Brook LLC (D. Del. 2019)
| Docket | See Plans and Pricing | Date Filed | 2019-02-28 |
| Court | District Court, D. Delaware | Date Terminated | 2021-08-30 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | Christopher J. Burke |
| Parties | ALVOGEN PINE BROOK LLC; JANSSEN BIOTECH, INC.; NATCO PHARMA LTD.; PHARMACYCLICS LLC | ||
| Patents | 10,004,746; 10,010,507; 10,016,435; 10,106,548; 10,106,591; 10,125,140; 10,213,386; 10,213,415; 10,294,231; 10,294,232; 10,434,140; 10,548,850; 6,346,532; 7,342,117; 7,514,444; 7,879,828; 7,982,049; 8,008,309; 8,476,284; 8,497,277; 8,563,563; 8,697,711; 8,703,780; 8,735,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 8,999,999; 9,018,192; 9,125,889; 9,181,257; 9,192,591; 9,192,662; 9,296,753; 9,302,002; 9,386,990; 9,415,004; 9,415,009; 9,540,382; 9,655,850; 9,655,857; 9,662,415; 9,713,617; 9,725,455; 9,752,191; 9,795,604; 9,801,881; 9,801,883; 9,814,721 | ||
| Attorneys | Chanson Chang; Christopher D. Lynch; Cristina L. Martinez; David M. Hanna; David S. Denuyl; Hannah Lee; Irena Royzman; Jack B. Blumenfeld; James L. Higgins; Jeffrey J. Lyons; Jeremy A. Tigan; Marcus A. Colucci; Melanie K. Sharp; Michelle M. Ovanesian; Steven W. Lee | ||
| Firms | Baker & Hostetler; Morris, Nichols, Arsht & Tunnell; Proskauer Rose LLP; Young, Conaway, Stargatt & Taylor LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pharmacyclics LLC v. Alvogen Pine Brook LLC
The small molecule drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Biologic Drugs cited in Pharmacyclics LLC v. Alvogen Pine Brook LLC
The biologic drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Details for Pharmacyclics LLC v. Alvogen Pine Brook LLC (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-02-28 | 1 | Complaint | PageID #: 2 Patent”); 9,655,857 (“the ’857 Patent”); 9,725,455 (“the ’455 Patent”); 10,010,507 (“the ’507… United States Patent Nos. 7,514,444 (“the ’444 Patent”); 8,008,309 (“the ’309 Patent”); 8,476,284 (“…(“the ’284 Patent”); 8,497,277 (“the ’277 Patent”); 8,697,711 (“the ’711 Patent”); 8,735,403 (“the ’403…’403 Patent”); 8,754,090 (“the ’090 Patent”); 8,754,091 (“the ’091 Patent”); 8,952,015 (“the ’015 Patent…507 Patent”); 10,106,548 (“the ’548 Patent”); and 10,125,140 (“the ’140 Patent”). | External link to document |
| 2019-06-10 | 14 | Amended Complaint | : 1565 Patent”); 9,655,857 (“the ’857 Patent”); 9,725,455 (“the ’455 Patent”); 10,010,507 (“the ’507… United States Patent Nos. 7,514,444 (“the ’444 Patent”); 8,008,309 (“the ’309 Patent”); 8,476,284 (“…(“the ’284 Patent”); 8,497,277 (“the ’277 Patent”); 8,697,711 (“the ’711 Patent”); 8,735,403 (“the ’403…’403 Patent”); 8,754,090 (“the ’090 Patent”); 8,754,091 (“the ’091 Patent”); 8,952,015 (“the ’015 Patent…507 Patent”); 10,106,548 (“the ’548 Patent”); 10,125,140 (“the ’140 Patent”); and 10,213,386 (“the ’ | External link to document |
| 2019-06-10 | 15 | Patent/Trademark Report to Commissioner | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,213,386 . (Blumenfeld, Jack…2019 30 August 2021 1:19-cv-00434 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-03-12 | 180 | Notice of Service | Non-Obviousness Relating to, U.S. Patent Nos. 9,725,455, 9,296,753, 10,106,548 and 10,125,140, (7) Opening …. Rule, B.M.B.S. Regarding Infringement of U.S. Patent No. 8,754,090 and Objective Indicia of Non-Obviousness…Regarding Objective Indicia of Nonobviousness of U.S. Patent Nos.9,655,857, (10) Opening Expert Report of Robert…Regarding Objective Indicia of Nonobviousness of U.S. Patent Nos. 10,294,231 and 10,294,232 and (11) Opening…Bodmeier Regarding Alvogen's Infringement of U.S. Patent No. 9,655,857 filed by Janssen Biotech, Inc., Pharmacyclics | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
